news

CDMO awarded $850,000 contract for development of Acute Cannabinoid Overdose treatment

6
SHARES

Under the contract, IRISYS LLC will develop a new, injectable formulation of drinabant that can rapidly and effectively reverse the symptoms of Acute Cannabinoid Overdose (ACO).

leaves of the marajuana plant overlaid with a pipette releasing a drop of oil containing cannabinoids

A contract development and manufacturing organisation (CDMO) has been awarded a contract worthĀ $850,000Ā by theĀ US National Center for Advancing Translational SciencesĀ (NCATS), to develop a new injectable formulation of drinabant, a selective, high affinity cannabinoid receptor (CB-1) antagonist.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report !Ā Access now – it’s free

Drinabant is being developed by Opiant Pharmaceuticals, Inc. to treat individuals who have ingested large quantities of tetrahydrocannabinol (THC) – the principal active constituent of cannabis – or synthetic cannabinoids and are diagnosed with Acute Cannabinoid Overdose (ACO). There are currently no US Food and Drug Administration approved treatments for ACO.

Severe symptoms of ACO can include panic, anxiety, feelings of paranoia, agitation, visual and auditory hallucinations and nausea, which may take several hours or days to fully resolve.

The overall goal of the project is for the CDMO, IRISYS LLC, to develop a formulation of drinabant for parenteral administration that can reverse the symptoms of ACO rapidly and effectively.Ā According to IRISYS, this is particularly important as young children are especially vulnerable to ACO as a result of mistakenly consuming THC containing edibles, such as brownies, cookies and candies with large quantities of THC.

Opiant originally identified this potential new use for drinabant, the NCATS Therapeutic Development Branch (TDB) then collaborated with them to optimise the drinabant drug product formulation and conduct toxicology/safety evaluation studies. IRISYS was then chosen, via a competitive bidding process, to develop a formulation for parenteral administration and manufacture it for use in Investigational New Drug (IND)-enabling studies and a Phase I clinical trial. IRISYS will also perform stability studies for three years.

“The need to quickly and effectively reverse ACO symptoms, including in vulnerable populations like children, is aĀ strong motivating factor pushing us at IRISYS every day to put in the effort needed to ensure that this drug is ready for clinical trials as soon as possible,” stated DrĀ Robert Giannini, IRISYS president and Chief Scientific/Technical Officer.

This project has been funded in whole or in part with Federal funds from NCATS, under Contract Number HHSN271201700020I.

2 responses to “CDMO awarded $850,000 contract for development of Acute Cannabinoid Overdose treatment”

  1. Scott says:

    Hi Hannah,

    Any idea how close drinabant is to clinical trials? This seems like a useful drug to me but unsure if any safety data is available.

    thanks,

    Scott

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Share via